

ITGB2, ITGAL, ITGAM

Research Grade Rovelizumab

Catalog No.	DHC13102A DHC13102B	Quantity:	100 µg 1.0 mg
Alternate Names:	Bispecific, Hu23F2G, 23F2G, CAS: 339086-79-2		
Description:	Research Grade Rovelizumab is a humanized monoclonal antibody which targets Integrin beta-2 (CD18) & Integrin alpha-L (CD11a) + Integrin alpha-M (CD11b)		
UniProt ID (target):	P05107, P20701, P11215		
Specificity:	Human Integrin beta-2, Integrin alpha-L, Integrin alpha-M		
Source:	XtenCHO cell line		
Isotype:	Human IgG4-nd		
INN:	Rovelizumab		
Concentration:	1.0 mg/ml, lot specific		
Formulation:	0.01M PBS, pH 7.4.		
Purity:	> 95% as determined by SDS-PAGE		
Purification:	Protein A/G affinity chromatography		
Endotoxin:	≤ 0.01 EU/µg by LAL analysis		
Storage & Stability:	Recommended storage, undiluted at 2-8°C for up to 1 week, or in working aliquots at -20°C to -80°C for up to 1 year. Avoid freeze/thaw cycles.		

NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.